The influence of hormone therapy with drospirenone-estradiol on endometrioid type endometrial cancer patients / 부인종양
Journal of Gynecologic Oncology
;
: e72-2018.
Article
Dans Anglais
| WPRIM
| ID: wpr-717066
ABSTRACT
OBJECTIVE:
To determine whether drospirenone/estradiol (DRSP/E2) has an adverse effect on clinical outcomes in surgically staged International Federation of Gynecology and Obstetrics (FIGO) stage I/II endometrial cancer (EC) patients.METHODS:
In a retrospective case-controlled study, 58 women with EC who had received DRSP/E2 postoperatively were compared with 116 women who had not. And, oncologic safety of postoperative hormone therapy with DRSP/E2 in EC survivors were compared between the 2 groups after propensity score matching using a logistic regression model.RESULTS:
The median ages were 47.7 years and 53.6 years for the study and the control groups, respectively (p < 0.001). The study group had similar parity (p = 0.71), lower body mass index (p = 0.03) and more premenopausal women (p < 0.001) than the control group. The stages were completely matched. The grades (p = 0.42), lymphovascular space invasion (p = 0.23), preoperative cancer antigen 125 (CA 125) level (p = 0.89), and hormone receptor status (p = 0.07) were similar in both groups. The median tumor diameter was statistically larger in the study group than in the control group (p < 0.001). Both group received similar adjuvant therapy (p = 0.80). In the propensity matching, only hormone receptor status was significantly different (p = 0.03). In the univariate analysis, only stage was significantly associated with disease-free survival (DFS) and there was no variable associated with overall survival (OS). And, there was no significant factor identified in multivariate analysis. The difference in the DFS (p = 0.63) and in the OS (p = 0.32) was not significant. The same results were obtained after propensity score matching.CONCLUSION:
Postoperative hormone therapy with DRSP/E2 in EC survivors did not increase recurrence or the death rate.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Parité
/
Récidive
/
Indice de masse corporelle
/
Études cas-témoins
/
Modèles logistiques
/
Analyse multifactorielle
/
Études rétrospectives
/
Mortalité
/
Tumeurs de l'endomètre
/
Survivants
Type d'étude:
Étude observationnelle
/
Étude pronostique
/
Facteurs de risque
Limites du sujet:
Femelle
/
Humains
langue:
Anglais
Texte intégral:
Journal of Gynecologic Oncology
Année:
2018
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS